Amiodarone is a valuable drug for the treatment of supraventricular and ventricular arrhythmias. However, toxicity involving a variety of organs and tissues that limits the agent's clinical use is not uncommon. This article presents the case of a patient who developed amiodarone-induced pulmonary fibrosis and blue-gray facial pigmentation. The authors emphasize awareness of amiodarone's toxicity profile and the importance of appropriate treatment and followup care. Patients should be educated to take an active role in this process by monitoring themselves for symptoms of amiodarone-induced pulmonary toxicity, to aid in early diagnosis and help prevent fatal outcomes.
American Society of Health-System Pharmacists.AHFS Drug Information.Bethesda, MD: ASHP; 2001, 1517–31.
17.
RasppersbergerK., HönigsmannH., OrtelB.Photosensitivity and hyperpigmentation in amiodarone-treated patients: Incidence, time course and recovery.J Invest Dermatol.1989; 93: 201–9.
18.
KounisN.G., FrangidesC., PapadakiP.J.Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation.Clin Cardiol.1996; 19: 592–4.
19.
KarrerS., HohenleutnerU., SzeimiesR-MAmiodarone-induced pigmentation resolves after treatment with the Q-switched ruby laser.Arch Dermatol.1999; 133: 251–3.
20.
MurphyJ.A., FitzsimonsB.M., MeuteM.A.Amiodarone: A postmarketing evaluation of monitoring for drug-induced toxicity.Drug Intell Clin Pharm.1990; 24: 1001–6.
21.
Alonso-HernándezP., Otero-LópezM.J., Calderón-GuadillaR.M.Seguimiento de la función tiroidea en pacientes tratados con amiodarona.Rev Clín Esp.2000; 200: 527–8.
